| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.suvenpharm.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 12,314.58 Cr. | |
| Earnings per share (EPS) | 14.23 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 33.99 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 33.86 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 46.39 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 10.43 | Calculated using Price: 483.75 |
| Dividend Yield | 0.52 | Period Ending 2020-03 |
| No. of Shares Subscribed | 25.46 Cr. | 254,564,957 Shares |
| FaceValue | 1 | |
| Company Profile | ||
|
Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020. Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement. The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company. Business area of the company The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. Business segments
|
||
Company Profile
Suven Pharmaceuticals Limited, a company incorporated in November 2018, has become Wholly Owned Subsidiary of Suven Life Sciences Limited, effective February 2019. Suven Life Sciences Limited, post the Board meeting on February 5, 2019, announced demerger of Suven Life Sciences Limited into: Suven Life Sciences Limited, the demerged entity, to continue innovative research focused on Central Nervous System (CNS) disorders to meet huge unmet global medical needs. Suven Pharmaceuticals Limited, the resultant entity, to continue the CRAMS business operations. The Scheme of Arrangement has since been approved by the National Company Law Tribunal (NCT), Hyderabad bench vide its order on 6th January 2020.
Pursuant to the Scheme of Arrangement between Suven Life Sciences Limited (‘Demerged Company’), Suven Pharmaceuticals Limited (‘Resulting Company’) and their respective shareholders and creditors, duly approved by the National Company Law Tribunal (NCLT), Hyderabad Bench, vide its Order dated 06th January, 2020, the Demerged Undertaking (as defined in the Scheme) of the Demerged Company has been demerged from Suven Life Sciences Limited and the same has been transferred to and vested in Suven Pharmaceuticals Limited with effect from 1st October, 2018, being the Appointed Date fixed in the said Scheme of Arrangement.
The Scheme, has become operative from the Appointed Date i.e., 1st October, 2018, but has become effective on 9th January, 2020 being the date on which certified copies of the Order of the NCLT, Hyderabad Bench sanctioning the Scheme was filed with the Registrar of Companies, Hyderabad, Telangana, both by the Demerged Company and Resulting Company.
Business area of the company
The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.
Business segments
| 1 Day |
|
-0.55% |
| 1 Week |
|
-3.38% |
| 1 Month |
|
-7.02% |
| 3 Month |
|
-0.17% |
| 6 Month |
|
+12.17% |
| 1 Year |
|
+191.54% |
| 2 Year |
|
|
| 5 Year |
|
| 2 years | 2019-03 | 2020-03 | |
| Return on Equity (%) | 18.92 | 37.80 | |
| Return on Capital Employed (%) | 23.87 | 44.55 | |
| Return on Assets (%) | 13.39 | 25.50 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 590 | 845 | |
| Non Curr. Liab. | 35 | 128 | |
| Curr. Liab. | 191 | 320 | |
| Minority Int. | |||
| Equity & Liab. | 816 | 1,292 | |
| Non Curr. Assets | 393 | 781 | |
| Curr. Assets | 423 | 511 | |
| Misc. Exp. not W/O | |||
| Total Assets | 816 | 1,292 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 378 | 834 | |
| Other Income | 1 | 18 | |
| Total Income | 378 | 852 | |
| Total Expenditure | -206 | -449 | |
| PBIDT | 172 | 403 | |
| Interest | -3 | -23 | |
| Depreciation | -12 | -24 | |
| Taxation | -49 | -88 | |
| Exceptional Items | |||
| PAT | 109 | 269 |
| Particulars | 2 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 50 | 416 | |
| Cash Fr. Inv. | -65 | -422 | |
| Cash Fr. Finan. | 26 | 6 | |
| Net Change | 11 | 1 | |
| Cash & Cash Eqvt | 11 | 12 |
|
Thu, 10 Jun 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release With reference to the above subject please find enclosed News Release of our company titled CSIR-IICT and SUVEN Pharmaceuticals Ltd. joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG. In this connection please further note that the TRADING WINDOW for dealing in the securities of the company which was closed from 01st April 2021 as per PIT Code of the Company stands extended till 13th June 2021. The trading window will be opened from 14th June 2021. This is for your information and record. |
|
Wed, 09 Jun 2021
Fixes Record Date for Final Dividend & AGM Suven Pharmaceuticals Ltd has informed BSE that the Company has fixed August 17 2021 as the Record Date for the purpose of Payment of Final Dividend & 3rd Annual General Meeting (AGM) of the Company to be held on August 31 2021. The final dividend will be paid on and from September 07 2021 within 30 days from the date of approval by members in the AGM. |
|
Wed, 09 Jun 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and year ended March 31 2021. The advertisements as appeared today i.e. June 9 2021 in Business Standard and Andhra Prabha (Telugu). The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements |
| Mon, 14 Jun 2021 |
Stock Underperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Underperforming Sectoral Index in both 1 Week and 3 Month
|
Strongly Underperforming Sectoral index
|
Closing Near 100 EMA
|
-DI crossing 25 from below
|
Equities
M.F.
Sectors